Atlas Trials

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

Clinical trial NCT05636319 · UNKNOWN

Trial details

NCT number
NCT05636319
Sponsor
Suzhou Abogen Biosciences Co., Ltd.
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2022-11-23
Primary completion
2023-04-30
Enrollment
14168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.